• Mason-Pfizer monkey virus (M-PMV) derived from breast tumor tissue of an 8 years-old female rhesus macaque (Macaca mulatta) in 1970 by Dr. Harish C. Chopra and Marcus M. Mason. (wikipedia.org)
  • Scholars@Duke publication: Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. (duke.edu)
  • The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. (duke.edu)
  • We compared the immunogenicity and relative efficiency of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum. (duke.edu)
  • IMPORTANCE Studies suggest that the protection against SIV/simian-human immunodeficiency virus (SHIV) acquisition afforded by the SIV/HIV V1 deletion-containing envelope immunogens, delivered by the DNA/ALVAC vaccine platform, requires multiple innate and adaptive host responses. (bvsalud.org)
  • We report here that the efficacy of DNA/ALVAC/gp120/alum vaccines, based on V2-specific antibodies mediating apoptosis of infected cells (V2-ADCC), is complemented by efferocytosis, a cyclic AMP (cAMP)-dependent antiphlogistic engulfment of apoptotic cells by CD14+ monocytes. (bvsalud.org)
  • To prevent the infection of this virus, two vaccines have been developed: a formalin-inactivated vaccine SRV-1 and a recombinant vaccine expressing M-PMV envelope glycoprotein gp70 and gp22. (wikipedia.org)
  • Mason-Pfizer monkey virus (M-PMV), formerly Simian retrovirus (SRV), is a species of retroviruses that usually infect and cause a fatal immune deficiency in Asian macaques. (wikipedia.org)
  • Shortly after its discovery, M-PMV was considered to induce simian AIDS (SAIDs). (wikipedia.org)
  • Here we report that the risk of vaginal simian immunodeficiency virus (SIV)mac251 acquisition is reduced by more than 90% using a combination of a vaccine comprising V1-deleted (V2 enhanced) SIV envelope immunogens with topical treatment of the zinc-finger inhibitor SAMT-247. (bvsalud.org)
  • The monoclonal antibodies (MAbs) NCI05 and NCI09, isolated from a vaccinated macaque that was protected from multiple simian immunodeficiency virus (SIV) challenges, both target an overlapping, conformationally dynamic epitope in SIV envelope variable region 2 (V2). (bvsalud.org)
  • However, the FLSC vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac251 acquisition. (duke.edu)
  • We also found that passive administration of NCI05 or NCI09 to macaques did not affect the risk of SIVmac251 acquisition compared to controls, demonstrating that these anti-V2 antibodies alone are not protective. (bvsalud.org)
  • Central to vaccine efficacy is the engagement of the CCL2/CCR2 axis and tolerogenic dendritic cells producing IL-10 (DC-10). (bvsalud.org)
  • Epigenetic reprogramming in CD14+ cells of the cyclic AMP/CREB pathway and increased systemic levels of miRNA-139-5p, a negative regulator of expression of the cAMP-specific phosphodiesterase PDE4D, correlated with vaccine efficacy. (bvsalud.org)
  • Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. (lookformedical.com)
  • Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. (duke.edu)
  • In both vaccine regimens, anti-V2 Abs correlated with a decreased risk of virus acquisition but differed with regard to systemic or mucosal origin. (duke.edu)
  • Anti-inflammatory macrophages and tolerogenic dendritic cells (DC-10), together with CD14+ efferocytes, are consistently found to correlate with a vaccine-induced decrease in the risk of SIV/SHIV acquisition. (bvsalud.org)
  • The development of an effective vaccine to protect against HIV acquisition will be greatly bolstered by in-depth understanding of the innate and adaptive responses to vaccination. (bvsalud.org)
  • The ssRNA virus appears sporadically in mammary carcinoma of captive macaques at breeding facilities which expected as the natural host, but the prevalence of this virus in feral macaques remains unknown. (wikipedia.org)
  • Mason-Pfizer monkey virus (M-PMV) derived from breast tumor tissue of an 8 years-old female rhesus macaque (Macaca mulatta) in 1970 by Dr. Harish C. Chopra and Marcus M. Mason. (wikipedia.org)
  • SRV-1 serotype was identified in the early 1980s in rhesus macaque, M. cyclopis, and M. fascicularis at National Primate Research Center (NPRC), California and New England. (wikipedia.org)
  • 16. Rhesus lymphocryptovirus infection during the progression of SAIDS and SAIDS-associated lymphoma in the rhesus macaque. (nih.gov)
  • Scientists soon realized that the disease affecting the animals was transmissible, but it was not until 1984 that it was determined that it was caused by a retrovirus and that it had probably come from Africa in macaques or other monkeys. (nih.gov)
  • Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). (umassmed.edu)
  • To prevent the infection of this virus, two vaccines have been developed: a formalin-inactivated vaccine SRV-1 and a recombinant vaccine expressing M-PMV envelope glycoprotein gp70 and gp22. (wikipedia.org)
  • 3. CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques. (nih.gov)
  • 7. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques. (nih.gov)
  • 10. Persistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans. (nih.gov)
  • 11. Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection. (nih.gov)
  • Here, we review recent studies of T-cell-mediated control of HIV and SIV infection, and offer insight for the design of a successful T-cell-based HIV vaccine in the future. (ox.ac.uk)
  • 2. Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. (nih.gov)
  • 1. The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. (nih.gov)
  • Infectious disease, in turn, continues to be a major health concern and leading cause of morbidity and mortality worldwide, despite major advances in our understanding of the immune system, improvements in sanitation practices, and use of antibiotics, vaccines, and antiviral drugs. (nih.gov)
  • The SRV serotype-2 was found in endemic infections of pig-tailed monkey (M. nemestrina), cynomolgus macaques, a Japanese macaque (M. fuscata), at Washington NPRC, and in rhesus and Celebes black macaques (M. nigra) at Oregon NPRC. (wikipedia.org)
  • In order to determine whether the DNA of the viral genome could be used as a vaccine if the DNA were rendered noninfectious, we deleted the reverse transcriptase gene from SHIVKU2 and inserted this DNA (DeltartSHIVKU2) into a plasmid that was then used to test gene expression and immunogenicity. (nih.gov)
  • Ziani W, Shao J, Fang A, Connolly PJ, Wang X, Veazey RS, Xu H. Mucosal integrin a4?7 blockade fails to reduce the seeding and size of viral reservoirs in SIV-infected rhesus macaques. (umassmed.edu)
  • The well-described association between the expression of particular MHC class I molecules and successful containment of HIV or, in the macaque model, SIV replication provide a valuable starting point from which to evaluate more precisely what might constitute effective CD8(+) T-cell responses. (ox.ac.uk)
  • Some clinical and pathological symptoms of M-PMV-infected newborn rhesus macaques are diarrhea, weight loss, splenomegaly, lymphadenopathy, anemia, neutropenia, and neoplastic diseases (retroperitoneal fibromatosis or rare B-cell lymphomas). (wikipedia.org)
  • 6. Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques. (nih.gov)
  • The recent failure of the T-cell-based HIV vaccine trial led by Merck & Co., Inc. prompts the urgent need to refocus on the question of which T-cell responses are required to control HIV replication. (ox.ac.uk)
  • The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Mamu-B*08+ Rhesus Macaques. (umassmed.edu)